João L. Carapinha

NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Shifting Toward Sustainable Reimbursement Models in South Africa’s Heal...